I'm LongbridgeAI, I can summarize articles.Seres Therapeutics reported Q2 2026 revenue of $0.736M and net income of $4.581M, a significant turnaround from the prior year's loss. The company completed the sale of its VOWST business to SPN, generating near-term cash inflows. Operational restructuring included a 30% workforce reduction and pausing the SER-155 Phase 2 trial due to funding constraints. Pipeline progress continues with encouraging data for SER-155, SER-603, SER-428, and SER-147.
Seres Therapeutics, Inc. reported second-quarter 2026 results with revenue of $0.736M and net income attributable to common stockholders of $4.581M, or diluted EPS of $0.47, compared with no revenue, a net loss of $(19.855) M and diluted EPS of $(2.27) in the year-ago quarter.
Financial Highlights
- Revenue was $0.736M for 2Q 2026, versus $0.0M in 2Q 2025.
- Net income was $4.581M attributable to common stockholders for 2Q 2026, versus $(19.855) M in 2Q 2025.
- Diluted EPS was $0.47 for 2Q 2026, versus $(2.27) in 2Q 2025.
Business Highlights
- Revenue comprised grant revenue (CARB-X); there were no product sales. Management said milestone termination payments are expected to bridge near-term operations.
- Pipeline progress: advancing SER-155, SER-603, SER-428 and SER-147 with encouraging Phase 1b and investigator-sponsored study data; SER-155 showed reductions in bloodstream infections (BSI) and responses in irEC.
- Operational restructuring included roughly a 30% workforce reduction, a lease amendment to reduce space and costs, and a pause of the SER-155 Phase 2 trial pending funding.
- Strategic transaction: the sale of the VOWST business to SPN has closed, with cross-license and milestone arrangements reshaping the portfolio and near-term cash inflows.
- Clinical and translational readouts and publications supported the company’s microbiome- and barrier-integrity-focused approach, underpinning targeted development and partnership discussions.
Original SEC Filing: Seres Therapeutics, Inc. [ MCRB ] - 10-Q - Aug. 05, 2026